Novo Nordisk

OpenAI announced it has acquired Orchestra Bio, a four-year-old AI biotech software startup, for undisclosed terms. Orchestra Bio builds AI agents that help biopharma teams coordinate drug development operations, including financial tracking, clinical trial scheduling, and assessing how events such as manufacturing batch failures affect trial timelines. OpenAI will integrate Orchestra Bio's team and technology into Rosalind, its life sciences AI model, and the Rosalind Workbench tool. Orchestra Bio had reportedly raised around $20 million as of 2025 from investors including Andreessen Horowitz, Atria, and 8VC.

5 reports · 5 sources · Updated Oct 20, 08:35 PM UTC

Over 90 US lawsuits have been filed since 2025 against Novo Nordisk and Eli Lilly, alleging their GLP-1 drugs semaglutide and tirzepatide caused non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition that can lead to permanent blindness. Novo Nordisk disputes the claims, citing a large randomized controlled trial that found no increased NAION risk. Eli Lilly says it will continue reviewing data. Regulatory warnings have been added in Europe, the UK, Japan, Australia, and New Zealand.

14 reports · 7 sources · Updated Sep 25, 09:49 AM UTC

On September 24, Swedish drug delivery company Nanexa announced a global exclusive license and collaboration agreement with Novo Nordisk valued at up to €1.165 billion ($1.3 billion). The deal grants Novo Nordisk exclusive rights to Nanexa's PharmaShell atomic layer deposition drug delivery platform for peptide drugs targeting obesity, type 2 diabetes, and other cardiometabolic indications. Nanexa is eligible for €615 million in upfront and milestone payments plus low single-digit royalties on net sales. Nanexa shares surged over 160% on September 25.

8 reports · 6 sources · Updated Sep 25, 08:19 AM UTC

On September 21, 2026, Novo Nordisk held its Capital Markets Day in London, unveiling a 2030 strategy to launch over five blockbuster drugs and achieve over $23 billion in pipeline sales by 2035. The market reacted sharply, with shares falling up to 8% in US and European trading, as investors were disappointed by the lack of short-term catalysts and the company's projection of 2026-2030 revenue growth in line with industry peers. CEO Mike Doustdar acknowledged the looming patent cliff for semaglutide in 2032 and the need to rebuild investor trust. The company also disclosed 13,000 job cuts from restructuring.

31 reports · 19 sources · Updated Sep 24, 02:11 PM UTC

Stronger-than-expected US September PMI data, with the composite index rising to 58.4 (highest since July 2021), triggered a sharp sell-off in US Treasuries, pushing the 10-year yield above 5% for the first time since 2007. This, combined with hawkish comments from Fed Governor Michael Barr, drove market expectations for an October rate hike to around 70%. US stocks fell sharply (Nasdaq -1.13%), European indices declined, and Asian markets also dropped. Oil prices surged, while gold and cryptocurrencies fell.

12 reports · 8 sources · Updated Sep 24, 07:11 AM UTC

AI company Anthropic is in early-stage negotiations to lease up to 1 gigawatt of computing capacity from a data center developer majority-owned by Apollo Global Management, seeking to bypass cloud providers and reduce costs. The move involves deploying TPUs designed by Broadcom and Google. Separately, investor Michael Burry increased short positions against Micron Technology, Nebius, and Palantir, warning of a potential "violent sell-off" from a memory cycle reversal.

6 reports · 6 sources · Updated Sep 23, 12:50 PM UTC

Novo Nordisk CEO Mike Doustdar stated the company is open to upgrading its New York listing from American Depositary Receipts (ADRs) to a direct listing on the New York Stock Exchange, following a similar move by AstraZeneca. The US market accounts for over half of Novo Nordisk's revenue and a growing share of its investor base. However, Doustdar emphasized there are no active discussions or studies on the proposal.

6 reports · 4 sources · Updated Sep 23, 06:46 AM UTC

On September 18, ten Chinese government departments, led by the Ministry of Industry and Information Technology, issued the "15th Five-Year Plan for Pharmaceutical Industry Development," targeting over 3.5 trillion yuan in revenue and 20% annual growth for innovative drugs by 2030. The plan emphasizes AI, quantum computing, and supercomputing in drug R&D. On September 21, A-share and Hong Kong pharmaceutical stocks surged, with the CRO index rising over 5% and nearly 20 stocks hitting daily limits. The National Healthcare Security Administration also introduced a pre-pricing system for new medical technologies.

16 reports · 13 sources · Updated Sep 23, 03:14 AM UTC

Chinese authorities in Guangzhou arrested 53 suspects and seized over 8,000 boxes of pharmaceuticals, primarily Novo Nordisk's semaglutide, in a "returned drug" trafficking ring. The drugs, requiring cold-chain storage at 2-8°C, were found in warehouses exceeding 30°C. Novo Nordisk China on September 22 stated it fully supports and will cooperate with authorities in cracking down on such illegal activities to protect medical insurance funds and patient safety.

12 reports · 9 sources · Updated Sep 22, 09:30 AM UTC

On September 21, China's Vice Minister of Commerce Ling Ji chaired a roundtable in Beijing with over 30 foreign-invested enterprises, including Cummins, Novo Nordisk, ABB, and Danaher. Ling Ji reaffirmed China's commitment to high-standard opening-up, providing stability for foreign firms. Participating companies expressed confidence in Beijing's business environment and innovation resources, pledging to deepen their presence in China.

6 reports · 5 sources · Updated Sep 22, 08:35 AM UTC

Novo Nordisk has partnered with Anthropic to integrate its Claude AI models, including Claude Science, into drug discovery and development workflows. The collaboration aims to accelerate R&D, automate clinical-trial report generation, and address complex biological challenges. Novo Nordisk CEO Mike Doustdar stated the company aims to become the world's "most AI-driven healthcare company." Financial terms and specific drug targets were not disclosed. The partnership expands Novo's existing AI collaborations with OpenAI and Amazon Web Services.

7 reports · 6 sources · Updated Sep 22, 01:48 AM UTC

Eli Lilly CEO Dave Ricks announced that Foundayo now accounts for one in three new oral weight-loss drug starts in the US, with market share growing weekly. The company broke ground on a $6.5 billion manufacturing facility in Houston, Texas, expected to be operational by 2030. Foundayo generated $98 million in second-quarter revenue since its April US launch. The drug competes with Novo Nordisk’s Wegovy pill, and Lilly held about 61% of the overall weight-loss and diabetes market in the second quarter.

6 reports · 2 sources · Updated Sep 21, 05:29 PM UTC

China's A-share market closed mixed on September 22, with the Shanghai Composite Index edging up 0.06% to 3952.13, while the Shenzhen Component Index fell 0.05%. AI applications and media stocks led gains, driven by Meta's AI agent Muse topping US iPhone downloads and Alibaba's AI investment pledge. CPU chip stocks rose after AMD surged and Haiguang Information launched its 1000-series CPU. Pharmaceutical stocks gained on mRNA tumor vaccine optimism. Total turnover reached approximately 2.14 trillion yuan.

59 reports · 17 sources · Updated Sep 21, 04:00 PM UTC